Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,976 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839.
Sparve E, Quartino AL, Lüttgen M, Tunblad K, Gårdlund AT, Fälting J, Alexander R, Kågström J, Sjödin L, Bulgak A, Al-Saffar A, Bridgland-Taylor M, Pollard C, Swedberg MD, Vik T, Paulsson B. Sparve E, et al. Among authors: alexander r. J Pharmacol Exp Ther. 2014 Aug;350(2):469-78. doi: 10.1124/jpet.114.215202. Epub 2014 Jun 10. J Pharmacol Exp Ther. 2014. PMID: 24917547 Free article. Clinical Trial.
Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers.
Quartino A, Huledal G, Sparve E, Lüttgen M, Bueters T, Karlsson P, Olsson T, Paraskos J, Maltby J, Claeson-Bohnstedt K, Lee CM, Alexander R, Fälting J, Paulsson B. Quartino A, et al. Among authors: alexander r. Clin Pharmacol Drug Dev. 2014 Sep;3(5):396-405. doi: 10.1002/cpdd.130. Epub 2014 May 26. Clin Pharmacol Drug Dev. 2014. PMID: 27129013 Clinical Trial.
BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.
Sakamoto K, Matsuki S, Matsuguma K, Yoshihara T, Uchida N, Azuma F, Russell M, Hughes G, Haeberlein SB, Alexander RC, Eketjäll S, Kugler AR. Sakamoto K, et al. Among authors: alexander rc. J Clin Pharmacol. 2017 Nov;57(11):1460-1471. doi: 10.1002/jcph.950. Epub 2017 Jun 15. J Clin Pharmacol. 2017. PMID: 28618005 Clinical Trial.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects.
Qiu R, Ahn JE, Alexander R, Brodney MA, He P, Leurent C, Mancuso J, Margolin RA, Tankisheva E, Chen D. Qiu R, et al. Among authors: alexander r. J Alzheimers Dis. 2019;71(2):581-595. doi: 10.3233/JAD-190228. J Alzheimers Dis. 2019. PMID: 31424395 Free PMC article. Clinical Trial.
Glutamate-based depression GBD.
McCarthy DJ, Alexander R, Smith MA, Pathak S, Kanes S, Lee CM, Sanacora G. McCarthy DJ, et al. Among authors: alexander r. Med Hypotheses. 2012 May;78(5):675-81. doi: 10.1016/j.mehy.2012.02.009. Epub 2012 Mar 4. Med Hypotheses. 2012. PMID: 22391030
Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients with X-Linked Hypophosphatemia.
Ali DS, Mirza RD, Hussein S, Alsarraf F, Alexander RT, Abu Alrob H, Appelman-Dijkstra NM, Biosse-Duplan M, Brandi ML, Carpenter TO, Chaussain C, Dandurand K, Filler G, Florenzano P, Fukumoto S, Grasemann C, Imel EA, Jan de Beur SM, Morgante E, Ward LM, Khan AA, Guyatt G. Ali DS, et al. Among authors: alexander rt. J Clin Endocrinol Metab. 2025 Jan 9:dgaf011. doi: 10.1210/clinem/dgaf011. Online ahead of print. J Clin Endocrinol Metab. 2025. PMID: 39787354
1,976 results